|
HER
2 IN BREAST CANCER
A NEW PROGNOSTIC AND PREDICTIVE FACTOR
BY
DR. ELIZABETH MALLON, PATHOLOGIST
THE WESTERN INFIRMARY, GLASGOW |
Breast Cancer is not a single disease.
Every breast cancer shows variable features and looks slightly
different microscopically, just as individuals look and behave
differently, so does an individuals breast cancer.
By looking at certain features of a
cancer, the Breast Team are able to predict how each cancer
is likely to behave and which treatments are required for
each individual. Many of these factors have been known about
for a long period of time. In the last few years a new factor
has emerged as a possible new prognostic and predictive factor
in breast cancer.
Prognostic factors determine if a tumour
is likely to have a good outlook or poor survival. Predictive
factors determine if a tumour is likely to respond to certain
treatments.
This new Factor is a protein known
as Her 2 (C-erb B 2, Her 2 neu). This protein is present in
all normal cells. Studies have demonstrated that in approximately
30% of breast cancers the tumour cells have an excess of this
protein. It has been suggested that in these cases the tumours
are likely to behave more aggressively, not respond as well
to certain treatments and respond more favourably to other
treatments. There is also a new form of treatment available
which only has effect in tumours with too much Her 2.
At the Western Infirmary our team hopes
to use the money raised by BREAST CANCER 2000 to look for
this protein in women we have treated with breast cancer.
This test was not routinely performed in the past. We are
very lucky in Glasgow to have treated large numbers of women
with breast cancer and have good follow up information on
the treatment received and the wellbeing of each woman. We
hope to correlate the results of Her 2 staining with the treatment
each individual woman has received and the outcome of that
treatment.
We are most grateful to BREAST CANCER
2000 for providing us with the large sum of money required
to perform these tests. We hope that the results produced
by this study will enable us to treat cases more effectively
in the future.
Dr Elizabeth Mallon
Consultant Pathologist
|